Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients (NCT07046806)
Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)
🩺 Plain-English Summary (8th-Grade Level)
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Who can join: Review the eligibility criteria below.
Location: Institute For Asthma & Allergy — Wheaton, Maryland
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Institute For Asthma & Allergy — Wheaton, Maryland
📞 Contact the Study Coordinator
Phone: (301) 962-5800
Email: info@allergyasthma.us
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Angioedema (HAE)
- A Study of Navenibart in Participants With Hereditary Angioedema — Birmingham, Alabama
- Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Little Rock, Arkansas
- A Phase 2 in Adult Subjects With Hereditary Angioedema — Silver Spring, Maryland
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Birmingham, Alabama
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) — Litchfield Park, Arizona
Explore by condition: All Hereditary Angioedema (HAE) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.